Navigation Links
Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

LAUSANNE, Switzerland, June 23 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that Salvacyl(R) (also known under the trade names Moapar(R) and Salvapar(R)), was launched in Germany in May 2009, by Dr R. Pfleger GmbH. In April 2009, Salvacyl(R) was also launched on a preliminary basis in Belgium. The effective commercial launch will take place in a couple of months. Salvacyl(R) contains the active substance triptorelin, a gonadotropin releasing hormone (GnRH) agonist analogue. The product will be prescribed for the reversible reduction of serum testosterone to the level of castration in order to lower sexual drive in adult men suffering from sexual deviations.

"This is a great accomplishment for Debiopharm. Salvacyl(R) is the fourth product we have developed and made available to doctors for the treatment of a serious condition," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We can now offer people suffering from this controversial disorder an alternative and a complementary treatment to surgical and currently used chemical castrations, as well as to other types of medication."

Salvacyl(R) is registered in seven other European countries, including France, the United Kingdom, Sweden, Norway, Denmark, the Netherlands and Finland, and will be launched progressively by Debiopharm's commercial partners in the course of 2009 and 2010. Moapar(R) is currently undergoing a registration procedure with Swissmedic in Switzerland.

About Salvacyl(R)

In the treatment of sexual deviations in men, intra-muscular administration of Salvacyl(R) every 3 months, in combination with psychotherapy, is an advantage over daily oral forms or intra-muscular weekly injections that are required with anti-androgens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA). There are also fewer side effects.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit:

    Debiopharm S.A. Contacts
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69

    Additional Media Contacts
    In London
    Brian Hudspith
    Tel: +44(0)20-7379-5151

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
5. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
6. More Than 300 New Medicines Being Developed for Mental Illnesses
7. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
8. Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists
9. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
10. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
11. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Post Your Comments:
(Date:10/12/2015)... ROSEMONT, Ill. , Oct. 12, 2015  To ... the American Academy of Orthopaedic Surgeons (AAOS) ... increase and improve physician, caregiver and patient education; the ... pain management; and support for more effective opioid abuse ... a member of the AAOS Patient Safety Committee. "The ...
(Date:10/12/2015)... 12, 2015 --> ... the global vital signs monitoring devices market in its upcoming ... and Opportunity Assessment 2015-2025." The global vital signs monitoring devices ... 9.5% and 9.2% in terms of value and volume, respectively, ... offers major insights in detail in this report. ...
(Date:10/12/2015)... Oct. 12, 2015   Royal Philips (NYSE: ... pathology, today announced a collaboration with Genomic Health ... provider of genomic-based diagnostic tests, to leverage Philips digital ... its molecular diagnostic testing processes.    ... of patient tissue samples and plays a crucial role ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... of telemedicine programs in communities throughout Georgia, along with affiliate organizations, Alabama Partnership ... for their regional telehealth summits for Fall 2015. , Each of the ...
(Date:10/13/2015)... FL (PRWEB) , ... October 13, 2015 , ... ... the Driveway Snow Blanket, a snow melting invention that helps people in clearing snow ... billion and will continue to grow at 3.8% per year," says Scott Cooper, CEO ...
(Date:10/13/2015)... ... October 13, 2015 , ... Breathing ... people do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and ... to breathe correctly, in concert with the 7,000 year old tradition they teach, ...
(Date:10/13/2015)... ... October 13, 2015 , ... CVS/pharmacy, the retail division ... for enrolling and serving insurance consumers who do not have a bank account, ... monthly premiums. In “Health Plan Engagement Strategies: The ABCs of Serving Consumers Who ...
(Date:10/13/2015)... Baltimore, MD (PRWEB) , ... October 13, 2015 ... ... and retailing sustainable and eco-friendly home furnishings and décor, today announced it closed ... growth equity investor. The funds will be used to support the Company’s continued ...
Breaking Medicine News(10 mins):